Optimizing Therapy for Patients with Acute and Chronic Graft-Versus-Host Disease (GvHD) - Episode 4

Treatment Options in Steroid-Refractory Acute GvHD

, , ,

Treatment options for steroid refractory acute GvHD, including ruxolitinib efficacy and NCCN guideline adherence, take center stage in the discussion.

Current Time 0:00
Duration 7:05
Loaded: 0%
Stream Type LIVE
Remaining Time 7:05
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
EP. 1: Understanding Chronic and Acute Graft-Versus-Host Disease Presentation and Diagnosis
EP. 2: Improving Patient Outcomes: Prophylactic Options in Graft-Versus-Host Disease
EP. 3: Optimal First-Line Treatment Approaches for Acute GvHD
Now Viewing
EP. 4: Treatment Options in Steroid-Refractory Acute GvHD
EP. 5: Enhancing Patient Care in Acute GvHD: Supportive Measures
EP. 6: Advancements and Promising Directions in Acute GvHD
EP. 7: Establishing Treatment Objectives for Chronic GvHD: First-Line Strategies
EP. 8: A Comprehensive Look at Initial Treatment Options for Chronic GvHD
EP. 9: Data-Driven Treatment Selection for Patients with Chronic GvHD
EP. 10: Remote Patient Monitoring and Supportive Care Measures in Chronic GvHD
EP. 11: The Future of Chronic GvHD Treatment
EP. 12: Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma
x